Led by $1bn acquisition of MediFox DAN Group, Europe’s medical devices industry saw a rise of 8.57% in cross border deal activity during Q2 2022, when compared to the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.


A total of 76 cross border deals worth $3.5bn were announced for the region during Q2 2022, against the last four-quarter average of 70.00 deals.

Of all the deal types, M&A saw most activity in Q2 2022 with 36 deals, representing a 47.4% share for the region.

In second place was venture financing with 31 deals, followed by private equity deals with nine transactions, respectively capturing a 40.8% and 11.8% share of the overall cross border deal activity for the quarter.

In terms of value of cross border deals, M&A was the leading category in Europe’s medical devices industry with $2.16bn, while private equity and venture financing deals totalled $874.2m and $464.06m, respectively.

Europe medical devices industry cross border deals in Q2 2022: Top deals

The top five medical devices cross border deals accounted for a 74.9% share of the overall value during Q2 2022.

The combined value of the top five cross border deals stood at $2.62bn, against the overall value of $3.5bn recorded for the quarter.

1) ResMed $1bn acquisition deal with MediFox DAN Group

2) The $797.86m private equity of SPT Labtech by EQT IX Fund

3) Wallaby Medical $541.63m acquisition deal with Phenox

4) The $141.73m acquisition of Aran Biomedical by Integer

5) Straumann $138.06m acquisition deal with SunshineSmile